Core Insights - Huatai Medical (688617) saw its stock price rise by 8.82% to 309.44 CNY as of September 5, 2025, with a market cap of 43.635 billion CNY, ranking 4th in the medical device sector [1][7] - A significant block trade occurred on September 3, 2025, at a discount of 21.31%, totaling 163 million CNY [2][7] Trading Information - On September 3, 2025, Huatai Medical executed a block trade with a total transaction value of 163 million CNY, at a price 21.31% lower than the closing price [2][7] Shareholder Changes - Shenzhen Mindray Technology Holdings Co., Ltd. increased its stake by acquiring 655,500 shares on September 3, 2025, raising its total ownership to 25.00% [3][7] Executive Changes - Yuchen Qiu, the Vice President, retired on September 1, 2025, and will no longer be recognized as a core technical personnel, although he will serve as a technical advisor [5][7] - The company's R&D team size has shown a steady increase, with 514 members as of June 30, 2025, indicating a stable technical system [5]

Core Viewpoint - Shenzhen Huatai Medical Instruments Co., Ltd. (the "Company") announced that its controlling shareholder, Shenzhen Mindray Technology Holdings Co., Ltd. ("Mindray"), increased its stake in the Company through a block trade, raising its ownership from 24.54% to 25.00% [2][4]. Group 1: Shareholding Changes - Mindray acquired an additional 655,536 shares, representing a 0.46% increase in its stake [2][3]. - Prior to this transaction, Mindray and its concerted party, Zhuhai Tongsheng Investment Partnership (Limited Partnership), held a total of 34,597,913 shares [2][3]. - Following the transaction, the total shares held by Mindray and Zhuhai Tongsheng increased to 35,253,449 shares [2][3]. Group 2: Transaction Details - The acquisition was executed through a block trade, with the total transaction amounting to approximately 162.70 million yuan, at a price of 248.20 yuan per share [27][28]. - The funds for this transaction were sourced entirely from Mindray's own or self-raised funds, with no involvement from the Company or its affiliates [3][28]. Group 3: Regulatory Compliance - The shareholding increase does not trigger a mandatory tender offer and will not result in a change of control of the Company [4][5]. - The transaction complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Management Measures for the Acquisition of Listed Companies [5][40]. Group 4: Future Plans - Mindray and its concerted party currently have no plans to further increase their stake in the Company within the next 12 months [24][30]. - There are no plans to change the Company's main business or make significant adjustments to its operations in the near future [30][31].

Core Insights - Huatai Medical (688617.SH) announced that Shenzhen Mindray Technology Holdings Co., Ltd. increased its stake through block trading by acquiring 655,536 shares at a price of 248.20 yuan per share, totaling 163 million yuan [1] - Following this equity change, Shenzhen Mindray and its concerted parties collectively hold 25.00% of the company's shares [1] Summary by Categories - **Equity Change** - Shenzhen Mindray increased its shareholding in Huatai Medical to 21.52% after the transaction [1] - The total amount invested in this transaction was 163 million yuan [1] - **Shareholding Structure** - Post-transaction, Shenzhen Mindray and its concerted parties own a combined 25.00% of Huatai Medical [1]

Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has shown a strong increase of 1.32% as of September 5, 2025, with notable gains in constituent stocks such as Zai Lab (688266) up 5.31%, Junshi Biosciences (688180) up 3.89%, and Huatai Medical (688617) up 3.85% [1] - Novartis continues to invest in siRNA technology, recently entering into a significant business development deal with BGI Genomics, involving an upfront payment of $160 million and a total potential milestone value of $5.2 billion [1] - According to Dongfang Securities, the performance of innovative drugs and the industry chain is strong, driven by the commercialization of domestic innovative products and the potential for international expansion [1] Industry Overview - The Sci-Tech Innovation Board Biopharmaceutical Index comprises 50 large-cap companies in the biopharmaceutical, biomedical engineering, biomedicine, and other related sectors, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Innovation Board [2] - As of August 29, 2025, the top ten weighted stocks in the index account for 50.27% of the total index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the index, providing investors with exposure to the biopharmaceutical sector [2]

Core Viewpoint - Shenzhen Huatai Medical Instruments Co., Ltd. announced that its controlling shareholder, Shenzhen Mindray Technology Holdings Co., Ltd., increased its stake in the company by 655,536 shares, representing a 0.46% increase in ownership [1] Group 1: Shareholding Changes - Before the transaction, Mindray and its concerted party, Zhuhai Tongsheng Investment Partnership, held a total of 34,597,913 shares, accounting for 24.54% of the total share capital [1] - After the transaction, their combined holdings increased to 35,253,449 shares, representing 25.00% of the total share capital [1] - The increase in shareholding does not trigger a mandatory tender offer and will not change the controlling shareholder or actual controller of the company [1] Group 2: Transaction Details - The share increase was executed through a block trade on September 3, 2025, at a price of 248.20 yuan per share [1] - The total number of shares purchased was 655,536, resulting in an increase of 0.4649% in ownership [1] - The funds for this transaction were sourced entirely from Mindray's own or self-raised funds, with no involvement from the company or its affiliates [1] Group 3: Compliance and Reporting - The shares involved in this transaction are unrestricted circulating shares, which enjoy voting rights without any limitations [1] - The transaction complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Management Measures for the Acquisition of Listed Companies [1] - A detailed report on the equity change has been disclosed on the Shanghai Stock Exchange's website [1]

Core Viewpoint - Shenzhen Huatai Medical Devices Co., Ltd. is undergoing a significant equity change, with Shenzhen Mindray Technology Holdings Co., Ltd. increasing its stake through a block trade, acquiring 655,536 shares, which represents 0.46% of the total share capital of Huatai Medical [1][2]. Group 1: Company Overview - Company Name: Shenzhen Huatai Medical Devices Co., Ltd. [1] - Stock Listing: Shanghai Stock Exchange, Stock Code: 688617.SH [1] - Registered Address: Shenzhen, Nanshan District, High-tech Industrial Park [1] - Information Disclosure Obligor: Shenzhen Mindray Technology Holdings Co., Ltd. [1] Group 2: Equity Change Details - The equity change involves a block trade executed on the Shanghai Stock Exchange [1]. - The transaction date is set for September 2025 [1]. - The increase in shares is part of a larger agreement involving multiple parties, including various investment entities [1][2]. Group 3: Financial Overview of Mindray Technology - Total Assets as of December 31, 2024: 1,600,345.57 million RMB [9] - Total Equity as of December 31, 2024: 1,354,513.21 million RMB [9] - Operating Revenue for 2024: 618,157.41 million RMB [9] - Net Profit for 2024: 85,252.93 million RMB [9] Group 4: Related Parties - Consistent control structure exists between Shenzhen Mindray and its subsidiaries, with key figures being Li Xiting and Xu Hang [2][10]. - Zhuhai Tongsheng Investment Partnership, a related party, has also been involved in the equity change, holding a significant stake in Huatai Medical [10]. Group 5: Compliance and Legal Standing - Shenzhen Mindray has not faced any administrative or criminal penalties in the last five years [9][10]. - The company maintains a clean legal record with no significant civil litigation or arbitration cases [9][10].

Core Viewpoint - Shenzhen Mindray Technology Holdings Co., Ltd. (referred to as "Mindray") has increased its stake in Huatai Medical by acquiring 655,500 shares through block trading, representing 0.46% of Huatai Medical's total share capital [1] Group 1: Shareholding Changes - After this equity change, Mindray and its concerted party, Zhuhai Tongsheng Investment Partnership (Limited Partnership), collectively hold 35,253,400 shares in Huatai Medical, accounting for 25.00% of the total share capital [1] - The increase in shareholding did not result in a change of control for Huatai Medical, as Mindray remains the controlling shareholder [1] Group 2: Transaction Details - The acquisition price was 248.20 yuan per share, with a total transaction amount of approximately 163 million yuan [1] - The information disclosure obligor has no plans to further increase or dispose of the shares held within the next 12 months [1]

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-042 深圳惠泰医疗器械股份有限公司 关于股东权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 深圳惠泰医疗器械股份有限公司（以下简称"公司"）控股股东深圳迈 瑞科技控股有限责任公司（以下简称"深迈控"）于 2025 年 9 月 3 日通过大宗 交易方式增持公司股份 655,536 股，增持比例为 0.46%。 本次权益变动前，深迈控及其一致行动人珠海彤昇投资合伙企业（有限 合伙）（以下简称"珠海彤昇"）合计持有公司股份 34,597,913 股，占公司总股 本的 24.54%；本次权益变动后，深迈控及其一致行动人珠海彤昇合计持有公司 股份 35,253,449 股，占公司总股本的 25.00%。 本次权益变动属于增持，不触及要约收购，不会导致公司控股股东或实 际控制人发生变化。 公司于近日收到深迈控及其一致行动人出具的《详式权益变动报告书》，现 将本次权益变动相关情况公告如下： 一、信息披露义务人及其一致行动人基本情况 | 序 ...

深圳惠泰医疗器械股份有限公司 详式权益变动报告书 上市公司名称：深圳惠泰医疗器械股份有限公司 股票上市地点：上海证券交易所 股票简称：惠泰医疗 股票代码：688617.SH 信息披露义务人：深圳迈瑞科技控股有限责任公司 注册地址：深圳市南山区高新技术产业园区高新南一路迈瑞总部大厦 3418 室 通讯地址：深圳市南山区高新技术产业园区科技南 12 路迈瑞大厦 一致行动人：珠海彤昇投资合伙企业（有限合伙） 注册地址：珠海市横琴新区豆蔻路 1 号粤澳合作中医药科技产业园科研总部 大楼 301 室 C06 号卡位 通讯地址：珠海市横琴新区豆蔻路 1 号粤澳合作中医药科技产业园科研总部 大楼 301 室 C06 号卡位 股份变动性质：股份增加（大宗交易） 一、本报告书系根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》及相关法律、法规和部门规章有关规定编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其行为亦不 违反信息披露义务人 ...

中信证券股份有限公司 关于 深圳惠泰医疗器械股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 2025年9月 中信证券股份有限公司关于深圳惠泰医疗器械股份有限公司详式权益变动报告书之财务顾问核查意见 声 明 根据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券 的公司信息披露内容与格式准则第15号——权益变动报告书》及《公开发行证券 的公司信息披露内容与格式准则第16号——上市公司收购报告书》等法律法规和 规范性文件的规定，中信证券股份有限公司（以下简称"本财务顾问"）按照行业 公认的业务标准、道德规范，本着诚实信用、勤勉尽责的精神，对本次权益变动 的相关情况和资料进行了核查，对信息披露义务人出具的《深圳惠泰医疗器械股 份有限公司详式权益变动报告书》所披露的内容出具核查意见，以供投资者和有 关各方参考。 为此，本财务顾问特作出以下声明： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《深圳惠泰医疗器械股份有限公司详式权益变动报告书》进行了核查，确信披露 文件内容与格式符合规定，并有充分理由确信所发表的专业意见与信息披露义务 人披露的文件内容不存在实质性差异； ...